Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
You must be a Standard 1 Year member to access this content.
Skadden is advising Otsuka, while Latham & Watkins is advising Jnana on the deal. Nutraceutical and pharmaceutical company Otsuka Holdings Co. Ltd., (Otsuka), announced the definitive...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Gurnet Point Capital in acquisition of Paratek Pharmaceuticals. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented MedAlliance in the transaction. Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...
You must be a Standard 1 Year member to access this content.
